Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Validation of the differential prognostic impact of type 1/type 1-like versus type 2/type 2-like CALR mutations in myelofibrosis

16 Oct 2015

Abstract excerpt

The discovery of mutations in calreticulin ( CALR ) in patients with primary myelofibrosis (PMF) 1 , 2 prompted a reappraisal of the clinical correlates and prognostic impact of the so-called driver mutations that include JAK2 V617F, MPL W515L/K/A and CALR in ~60%, 5–10% and 20–25% of patients, respectively. As compared with their JAK2 V617F counterpart, PMF patients harboring CALR mutations showed younger age,...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Chronic Myeloid Leukemia Treatments
Share to Kruppel-like factors research
Share to Myeloproliferative Neoplasms: Diagnosis and Treatment

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 26473532
DOI: 10.1038/bcj.2015.90

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Validation of the differential prognostic impact of type 1/type 1-like versus type 2/type 2-like CALR mutations in myelofibrosisPMID 26473532Read ↗

Driver mutations and prognosis in primary myelofibrosis: Mayo-Careggi MPN alliance study of 1,095 patients.Semantic proximity Read ↗

The prognostic advantage of calreticulin mutations in myelofibrosis might be confined to type 1 or type 1-like CALR variantsSemantic proximity Read ↗

CALR vs JAK2 vs MPL-mutated or triple-negative myelofibrosis: clinical, cytogenetic and molecular comparisons.Semantic proximity Read ↗

Type 1 vs type 2 calreticulin mutations in primary myelofibrosis: differences in phenotype and prognostic impactSemantic proximity Read ↗

CALR and ASXL1 mutations-based molecular prognostication in primary myelofibrosis: an international study of 570 patients.Semantic proximity Read ↗

Clinical effect of driver mutations of JAK2, CALR, or MPL in primary myelofibrosis.Semantic proximity Read ↗

Calreticulin mutation profile in Indian patients with primary myelofibrosis.Semantic proximity Read ↗

The different variant allele frequencies of type I/type II mutations and the distinct molecular landscapes in CALR-mutant essential thrombocythaemia and primary myelofibrosis.Semantic proximity Read ↗

Phenotypic correlations of CALR mutation variant allele frequency in patients with myelofibrosisSemantic proximity Read ↗

The characteristics of CALR mutations in myeloproliferative neoplasms: a clinical experience from a tertiary care center in Qatar and a literature review.Semantic proximity Read ↗

CALR type 1 mutations are associated with an increased incidence of myelofibrosis in young male patients.Semantic proximity Read ↗

CALR mutations in a cohort of JAK2 V617F negative patients with suspected myeloproliferative neoplasms.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.